IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9334288 B1

PDFFull Text
Date of Patent:
May. 10, 2016

Filed:

Sep. 23, 2013

Selective β-glucuronidase inhibitors as a treatment for side effects of camptothecin antineoplastic agents

Applicant:

The University of North Carolina AT Chapel Hill, Chapel Hill, NC (US);

Inventor:

Matthew R. Redinbo, Durham, NC (US);

Assignee:

The University of North Carolina at Chapel Hill, Chapel Hill, NC (US);

Attorney:

Alston & Bird LLP

Primary Examiner:

Samantha Shterengarts

Int. Cl.
CPC ...
A61K 31/335 (2006.01); A61K 31/00 (2006.01); A61K 31/38 (2006.01); A61K 31/435 (2006.01); A61K 45/06 (2006.01); A61K 31/381 (2006.01); A61K 31/4704 (2006.01); A61K 31/4745 (2006.01); A61K 31/496 (2006.01); A61K 31/519 (2006.01); A61K 31/5377 (2006.01); C07D 495/14 (2006.01); C07D 215/227 (2006.01); C07D 317/50 (2006.01); C07D 333/38 (2006.01); C07D 487/04 (2006.01); C07D 495/04 (2006.01);
U.S. Cl.
CPC ...
C07D 495/14 (2013.01); A61K 31/00 (2013.01); A61K 31/335 (2013.01); A61K 31/38 (2013.01); A61K 31/381 (2013.01); A61K 31/435 (2013.01); A61K 31/4704 (2013.01); A61K 31/4745 (2013.01); A61K 31/496 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); C07D 215/227 (2013.01); C07D 317/50 (2013.01); C07D 333/38 (2013.01); C07D 487/04 (2013.01); C07D 495/04 (2013.01);
Abstract

Compounds, compositions and methods are provided that comprise selective β-glucuronidase inhibitors for both aerobic and anaerobic bacteria, especially enteric bacteria normally associated with the gastrointestinal tract. The compounds, compositions and methods can be for inhibiting bacterial β-glucuronidase and for improving efficacy of camptothecin-derived antineoplastic agents or glucuronidase-substrate agents or compounds by attenuating the side effects caused by reactivation by bacterial β-glucuronidases of glucuronidated metabolites of camptothecin-derived antineoplasatic agents or glucuronidase-substrate agents or compounds.

Find Patent Forward Citations

Loading…